{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T07:22:04Z","timestamp":1693207324053},"reference-count":40,"publisher":"Georg Thieme Verlag KG","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Klin Monbl Augenheilkd"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Die Fr\u00fchgeborenenretinopathie z\u00e4hlt zu den h\u00e4ufigsten behandelbaren Erblindungsursachen bei Kindern. Es handelt sich um eine vasoproliferative Netzhauterkrankung, die nur bei Fr\u00fchgeborenen\n\t\t\t\t\tauftritt. Durch ein konsequentes augen\u00e4rztliches Screening k\u00f6nnen nahezu alle Augen mit behandlungsbed\u00fcrftiger ROP fr\u00fchzeitig identifiziert und einer Behandlung zugef\u00fchrt werden, sodass das\n\t\t\t\t\tRisiko einer schweren Sehbehinderung oder Erblindung durch eine ROP erheblich gesenkt wird.<\/jats:p>","DOI":"10.1055\/a-1758-3020","type":"journal-article","created":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T07:04:45Z","timestamp":1646636685000},"page":"346-363","source":"Crossref","is-referenced-by-count":1,"title":["Fr\u00fchgeborenenretinopathie"],"prefix":"10.1055","volume":"239","author":[{"given":"Jeany Q.","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Kellner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgit","family":"Lorenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim U.","family":"Krohne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2022,3,4]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/aos.13631","article-title":"Children with blindness \u2013 major causes, developmental outcomes and implications for habilitation and educational support: a two-decade, Swedish population-based study","volume":"96","author":"Kim de Verdier","year":"2018","journal-title":"Acta Ophthalmol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1007\/s00347-018-0683-3","article-title":"Fr\u00fchgeborenenretinopathie: Aktuelle Entwicklungen in Therapie und Epidemiologie","volume":"115","author":"T U Krohne","year":"2018","journal-title":"Ophthalmologe"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1016\/j.ophtha.2021.05.031","article-title":"International Classification of Retinopathy of Prematurity, Third Edition","volume":"128","author":"M F Chiang","year":"2021","journal-title":"Ophthalmology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1055\/a-1248-0649","article-title":"Augen\u00e4rztliche Screening-Untersuchung bei Fr\u00fchgeborenen (S2k-Level, AWMF-Leitlinien-Register-Nr.\u2009024\/010, M\u00e4rz 2020)","volume":"225","author":"R F Maier","year":"2021","journal-title":"Z Geburtshilfe Neonatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s00347-020-01170-x","article-title":"Deutsche Ophthalmologische Gesellschaft e.V. (DOG), Retinologische Gesellschaft e.V. (RG) & Berufsverband der Augen\u00e4rzte Deutschlands e.V. (BVA). Stellungnahme der Deutschen\n\t\t\t\t\tOphthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbands der Augen\u00e4rzte Deutschlands zur Anti-VEGF-Therapie der Fr\u00fchgeborenenretinopathie. Stand:\n\t\t\t\t\t18.05.2020","volume":"117","year":"2020","journal-title":"Ophthalmologe"},{"key":"ref6","first-page":"1217","article-title":"Vascularization of the human fetal retina: roles of vasculogenesis and angiogenesis","volume":"41","author":"S Hughes","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1055\/s-0031-1298436","article-title":"Fr\u00fchgeborenenretinopathie","volume":"2","author":"C Jandeck","year":"2012","journal-title":"Augenheilkunde up2date"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1542\/peds.2004-1915","article-title":"Age terminology during the perinatal period","volume":"114","author":"W A Engle","year":"2004","journal-title":"Pediatrics"},{"key":"ref9","first-page":"127","article-title":"An international classification of retinopathy of prematurity","author":"American Academy of Pediatrics","year":"1984","journal-title":"Pediatrics"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1001\/archopht.123.7.991","article-title":"The International Classification of Retinopathy of Prematurity revisited","volume":"123","author":"International Committee for the Classification of Retinopathy of Prematurity","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s00417-009-1077-7","article-title":"Wide-field digital imaging based telemedicine for screening for acute retinopathy of prematurity (ROP). Six-year results of a multicentre field study","volume":"247","author":"B Lorenz","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1136\/bjophthalmol-2019-314874","article-title":"New modifications of Swedish ROP guidelines based on 10-year data from the SWEDROP register","volume":"104","author":"G Holmstr\u00f6m","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"F337","DOI":"10.1136\/archdischild-2017-313574","article-title":"Incidence of retinopathy of prematurity (ROP) and ROP treatment in Switzerland 2006\u20132015: a population-based analysis","volume":"103","author":"R Gerull","year":"2018","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1136\/archdischild-2020-319767","article-title":"Incidence of retinopathy of prematurity in Germany: evaluation of current screening criteria","volume":"106","author":"P P Larsen","year":"2021","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1016\/j.jpedsurg.2019.07.021","article-title":"Retinal findings in neonates with congenital diaphragmatic hernia and extracorporeal membrane oxygenation","volume":"55","author":"P P Larsen","year":"2020","journal-title":"J Pediatr Surg"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1038\/s41372-019-0487-6","article-title":"Risk of development of treated retinopathy of prematurity in very low birth weight infants","volume":"39","author":"S Gonski","year":"2019","journal-title":"J Perinatol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"e20183061","DOI":"10.1542\/peds.2018-3061","article-title":"Screening Examination of Premature Infants for Retinopathy of Prematurity","volume":"142","author":"W M Fierson","year":"2018","journal-title":"Pediatrics"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jaapos.2014.01.016","article-title":"Risk and clinical course of retinopathy of prematurity in 78 infants of gestational age 22\u201325 weeks","volume":"18","author":"M M Miller","year":"2014","journal-title":"J AAPOS"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1007\/s00347-021-01393-6","article-title":"Screening auf Fr\u00fchgeborenenretinopathie \u2013 die wichtigsten \u00c4nderungen in der neuen deutschen Leitlinie 2020","volume":"118","author":"J Q Li","year":"2021","journal-title":"Ophthalmologe"},{"key":"ref20","first-page":"233","article-title":"Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial","volume":"102","author":"W V Good","year":"2004","journal-title":"Trans Am Ophthalmol Soc"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1038\/eye.2008.128","article-title":"UK retinopathy of prematurity guideline","volume":"23","author":"A R Wilkinson","year":"2009","journal-title":"Eye"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1001\/archopht.1988.01060130517027","article-title":"Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Cryotherapy for Retinopathy of Prematurity Cooperative Group","volume":"106","year":"1988","journal-title":"Arch Ophthalmol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/S0161-6420(91)32074-8","article-title":"Incidence and Early Course of Retlnonathy of Prematurity","volume":"98","author":"E A Palmer","year":"1991","journal-title":"Ophthalmology"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.ophtha.2016.04.028","article-title":"Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy","volume":"123","author":"H A Mintz-Hittner","year":"2016","journal-title":"Ophthalmology"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial","volume":"132","author":"M M Geloneck","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial","volume":"394","author":"A Stahl","year":"2019","journal-title":"Lancet"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3\u2009+ retinopathy of prematurity","volume":"364","author":"H A Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"e0148019","DOI":"10.1371\/journal.pone.0148019","article-title":"Neurodevelopmental Outcomes in Infants with Retinopathy of Prematurity and Bevacizumab Treatment","volume":"11","author":"R Lien","year":"2016","journal-title":"PLoS One"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"e20153218","DOI":"10.1542\/peds.2015-3218","article-title":"Neurodevelopmental Outcomes Following Bevacizumab Injections for Retinopathy of Prematurity","volume":"137","author":"J Morin","year":"2016","journal-title":"Pediatrics"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1001\/jamapediatrics.2017.4838","article-title":"Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity: A Randomized Clinical Trial","volume":"172","author":"A Stahl","year":"2018","journal-title":"JAMA Pediatrics"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/eye.2015.289","article-title":"Involution patterns of retinopathy of prematurity after treatment with intravitreal bevacizumab: implications for follow-up","volume":"30","author":"M Isaac","year":"2016","journal-title":"Eye"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jaapos.2015.01.009","article-title":"Treatment of type 1 retinopathy of prematurity with bevacizumab versus laser","volume":"19","author":"M Isaac","year":"2015","journal-title":"J AAPOS"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","article-title":"Reactivation of retinopathy of prematurity after bevacizumab injection","volume":"130","author":"J Hu","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jaapos.2010.05.011","article-title":"Delayed-onset retinal detachment after an intravitreal injection of ranibizumab for zone 1 plus retinopathy of prematurity","volume":"14","author":"S Y Jang","year":"2010","journal-title":"J AAPOS"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1097\/IAE.0000000000000578","article-title":"Reactivation of retinopathy of prematurity after ranibizumab treatment","volume":"35","author":"R K Wong","year":"2015","journal-title":"Retina"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jcjo.2014.11.005","article-title":"SUNDROP: six years of screening for retinopathy of prematurity with telemedicine","volume":"50","author":"S K Wang","year":"2015","journal-title":"Can J Ophthalmol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.clp.2013.02.007","article-title":"Optical coherence tomography in retinopathy of prematurity: looking beyond the vessels","volume":"40","author":"R S Maldonado","year":"2013","journal-title":"Clin Perinatol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.ophtha.2015.04.023","article-title":"Influence of fluorescein angiography on the diagnosis and management of retinopathy of prematurity","volume":"122","author":"M A Klufas","year":"2015","journal-title":"Ophthalmology"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1097\/IAE.0000000000001996","article-title":"Fluorescein angiographic evaluation of peripheral retinal vasculature after primary intravitreal ranibizumab for retinopathy of prematurity","volume":"39","author":"C A Harper III","year":"2019","journal-title":"Retina"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1055\/a-1012-1999","article-title":"Fluorescence angiography-assisted management of recurrences in aggressive posterior retinopathy of prematurity (APROP) after Intravitreal monotherapy with 0.312\u2009mg Bevacizumab","volume":"237","author":"M Andrassi-Darida","year":"2020","journal-title":"Klin Monbl Augenheilkd"}],"container-title":["Klinische Monatsbl\u00e4tter f\u00fcr Augenheilkunde"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1758-3020.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T14:11:26Z","timestamp":1676038286000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1758-3020"}},"subtitle":["Aktuelle Aspekte zu Klassifikation, Screening und Therapie"],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":40,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2022,3,22]]},"published-print":{"date-parts":[[2022,3]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1758-3020","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0023-2165","1439-3999"],"issn-type":[{"value":"0023-2165","type":"print"},{"value":"1439-3999","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3]]}}}